Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer

被引：0
|
作者：
Arrazubi, V [1 ]
Illarramendi, J. [1 ]
Lainez, N. [1 ]
Salgado, E. [1 ]
Martinez, M. [1 ]
Amillano, K. [1 ]
Vera, R. [1 ]
机构：
[1] Hosp Navarra, Pamplona, Spain
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [31] Gemcitabine and capecitabine improves survival in advanced pancreatic cancer patients
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (06) : 943 - 943
  • [32] Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer
    Hubner, Richard A.
    Worsnop, Fiona
    Cunningham, David
    Chau, Ian
    PANCREAS, 2013, 42 (03) : 511 - 515
  • [33] Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
    Kipps, Emma
    Young, Kate
    Starling, Naureen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (03) : 159 - 170
  • [34] A phase II study of paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil (POLF) in gemcitabine-refractory advanced pancreatic cancer
    Chue, Ben
    Grutsch, James
    Gupta, Digant
    Birdsall, John
    Lis, Christopher
    CANCER RESEARCH, 2009, 69
  • [35] Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
    Lee, Jeung Eun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Bang, Seungmin
    GUT AND LIVER, 2020, 14 (01) : 135 - 143
  • [36] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [37] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [38] Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
    Javle, M.
    Fogelman, D.
    Kaseb, A.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 104 - 104
  • [39] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [40] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
12345